Medical
Medexus Pharmaceuticals Returns U.S. Gleolan Rights to NX Development Corp.
Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) has finalized an agreement to transfer U.S. commercialization rights for Gleolan® back to NX Development Corp. (NXDC). This decision...
Pioneering Medical Imaging Technology Debuts in Tennessee Hospital
In a significant advancement for surgical oncology, Covenant Health Fort Sanders Regional has become the first hospital in Tennessee to adopt a cutting-edge imaging technology...
Arcuro Medical Secures FDA Clearance for Innovative Rotator Cuff Repair System
In a significant development for the medical device industry, Arcuro Medical Ltd., a portfolio company of The Trendlines Group (SGX: 42T, OTCQX: TRNLY) has announced...
Can Hemp Save California? Natural Building Advocates Push for Code Reform
California homeowners are facing a crisis. Wildfires are increasing in frequency and intensity, and the reliance on conventional, often toxic, building materials is exacerbating the...
Endo Pharmaceuticals Launches Patient-Centric Campaign for Xiaflex
Endo Pharmaceuticals (OTCQX: NDOI) is shifting its marketing strategy for Xiaflex, the only FDA-approved nonsurgical treatment for Dupuytren’s contracture, with the launch of a new...
Breakthrough COVID-19 Vaccine Gains European Approval
In a significant development for the biotechnology industry, the European Commission has authorized the marketing of KOSTAIVE, the first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine. This...
CSL Behring’s Hemophilia B Gene Therapy, HEMGENIX®, Shows Sustained Efficacy in Long-Term Study
CSL Behring (ASX: CSL, OTCQX: CSLLY) has released four-year data from its Phase 3 HOPE-B trial, demonstrating the long-term efficacy and safety of its gene...
Eli Lilly Fast-Tracks Retatrutide Data Release, Strengthening Position in Weight Loss Market
Eli Lilly (NYSE: LLY) has announced that data from a late-stage trial of its next-generation weight loss drug, retatrutide, is expected to be released later...
Orgenesis Receives Up to $5 Million Investment from Williamsburg Venture Holdings to Enhance CGT Platform
Orgenesis Inc. (OTCQX:ORGS), a global biotech company focused on advancing cell and gene therapies (CGT), has secured an equity investment of up to $5 million...
NanoViricides Partners with CRO to Advance Phase II Clinical Trials for NV-387
NanoViricides, Inc. (NYSE American: NNVC), based in Shelton, Connecticut, has announced a significant step in its clinical development pipeline by engaging a Clinical Research Organization...
